In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae

AUTOR(ES)

Roblin, Patricia M.

FONTE

American Society for Microbiology

RESUMO

The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniae were tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 μg/ml (range, 0.015 to 2 μg/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 μg/ml) than older strains that had been passaged more extensively.

Documentos Relacionados

• In Vitro Activity of ABT 773, a New Ketolide Antibiotic, against Chlamydia pneumoniae
• In Vitro Activities of Ketolide HMR 3647, Macrolides, and Clindamycin against Coryneform Bacteria
• In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan
• Interactions between HMR 3647, a New Ketolide, and Human Polymorphonuclear Neutrophils
• In Vitro Activities of the New Ketolide Antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany